Biotech: focusing on fundamentals



​The biotech industry is experiencing a renaissance, with the US approving a record number of novel therapies in 2018. But not all drugs are created equal, according to members of the Janus Henderson Global Life Sciences team, making it important for investors to focus on both the science and commercial potential of new medicines.

Innovation is a hallmark of biotechnology, and the medical breakthroughs that the industry is now delivering could arguably be called unprecedented. But even as the potential for growth ramps up, we believe investors need to take a prudent approach to investing in the sub-sector.

Innovation accelerates

In 2018, the US Food and Drug Administration (FDA) approved 59 novel therapies, the most of any year on record1. What’s more, the calibre of medicines was noteworthy, with many representing exciting advances for their disease categories, from rare life-threatening disorders to more common ailments.

Consider migraines, the severe headaches that afflict as many as one billion people globally2. For years, migraine drugs treated only the symptoms of the neurological condition. But last year, the FDA approved the first calcitonin gene-related peptide (CGRP) inhibitors. These antibodies work to block CGRP from binding to a receptor, believed to play a key role in the pathology of migraines. In clinical trials, patients treated with the inhibitors saw a significant reduction in the number of days they experienced symptoms. In other words, CGRPs help prevent migraines from developing in the first place, representing a marked improvement in quality of life.

Chart: US annual drug approvals

Source: US Food and Drug Administration, as at 31 December 2018. Note: drug totals are for new molecular entities.

Accommodative regulators

Regulators are helping facilitate these advances with faster pathways for drug approvals. The FDA, for one, now offers a breakthrough therapy designation, which expedites the review of medicines that address serious illness or improve the standard of care. The European Medicines Agency recently introduced a PRIME pathway, which aims to reduce review times for novel drugs by nearly a third. Finally, the Chinese Food and Drug Administration has for the first time begun to accept non-Chinese clinical trial data as part of its drug approval process. These avenues not only make it possible to bring drugs to market more quickly, but also reduce the cost of drug development.

Drug development ramping up

As more firms target these accelerated pathways, regulators are bracing for an explosion in advanced medicine applications. In 2019, the FDA is expected to approve AVXS-101, a gene therapy for infants affected by spinal muscular atrophy (SMA). The drug’s approval could be transformational for these young patients: SMA is the leading genetic cause of infant death globally3. It could also become a platform for the manufacture of other gene therapies – a key reason, in our opinion, for Novartis’ $8.7 billion acquisition last year of AveXis, the developer of AVXS-101. To that end, by 2025, the FDA estimates it will be approving 10 to 20 gene and cell therapies annually4.

In addition, other methods for targeting disease are becoming available. Last year, the FDA approved the first RNA interference (RNAi) therapeutic, Onpattro, for the treatment of peripheral nerve disease. RNAi works by using a gene’s own DNA sequence to turn off the expression of a malfunctioning gene. By silencing the sequence, Onpattro could essentially arrest, or even reverse, this painful hereditary condition. Other advanced therapies could have similar effects. For example, gene therapies involve creating a functional copy of a missing or defective gene. Once inserted into cells, the manufactured gene creates a protein that previously may have been missing from a patient, potentially curing the disease. And within cancer, great strides are being made with immunotherapies. These treatments involve disrupting inhibitors that prevent the immune system from recognising cancer cells, or re engineering T-cells (a type of immune cell) to target and kill cancer. Results have been impressive, with one immunotherapy, Keytruda (manufactured by Merck & Co.), reducing the risk of death for the most prevalent form of lung cancer by 50%.

Focusing on value

As exciting as these advances are, we believe investors should keep in mind that such progress can be disruptive and faces risk. For one, industry research has found that roughly 90% of compounds that enter human clinical trials never make it to market. In addition, our experience highlights that of therapies that do succeed, investors either over- or underestimate the commercial opportunity about 90% of the time. These odds can lead to dramatic moves in biotech stocks.

With these challenges in mind, we believe investors should be keenly focused on valuation, looking for stocks that trade below the scientific and commercial potential of a company’s products and pipeline. After the market’s pullback last year, we feel a number of biotech stocks offer attractive valuations, potentially leading to a pickup in mergers and acquisitions. Indeed, more than $80 billion of biotech deals were announced in the first month of 2019, highlighted by Bristol-Myers Squibb’s planned acquisition of Celgene.

We also think it is critical to look for companies developing medicines that add value to the healthcare system. The Institute for Clinical and Economic Review, an independent research organisation based in Boston, Massachusetts, is playing an increasing role in evaluating the clinical and economic value of new drugs. We believe companies will need to demonstrate the value of their medicines in order to obtain attractive levels of reimbursement.

This value could come into sharper focus as more countries attempt to balance rising costs, aging populations and increased living standards. In 2017, for example, China updated its National Reimbursement Drug List, which includes therapies approved for reimbursement in the country’s government-run health insurance programme (which covers nearly 100% of China’s population). It was the first update since 2009, and resulted in more than 300 new medicines being added to the list. China also recently approved immunotherapies from Merck and Bristol-Myers. Early data indicate that the launch trajectories for these cancer-fighting drugs in China could rival the rapid uptake in the US. We believe such demand could further fuel biotech’s impressive growth, and help the companies developing high-value drugs stand out.







The healthcare industries are subject to government regulation and reimbursement rates, as well as government approval of products and services, which could have a significant effect on price and availability, and can be significantly affected by rapid obsolescence and patent expirations.

These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. Any securities, funds, sectors and indices mentioned within this article do not constitute or form part of any offer or solicitation to buy or sell them.

Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

The information in this article does not qualify as an investment recommendation.

For promotional purposes.

Important information

Please read the following important information regarding funds related to this article.

Janus Henderson Global Life Sciences Fund

For institutional/ sophisticated investors / accredited investors qualified distributors use only.

All content in this document is for information or general use only and is not specific to any individual client requirements. The information contained in this document is referential and may not be construed as an offer, invitation or recommendation or investment advice, nor should be taken as a basis to take (or stop taking) any decision.

Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons.  Past performance is not indicative of future results. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements.  Shares, if redeemed, may be worth more or less than their original cost.

Janus Henderson Group plc and its subsidiaries are not responsible for any unlawful distribution of this document to any third parties, in whole or in part, or for information reconstructed from this document and do not guarantee that the information supplied is accurate, complete, or timely, or make any warranties with regards to the results obtained from its use. As with all investments, there are inherent risks that each individual should address.

The distribution of this document or the information contained in it may be restricted by law and may not be used in any jurisdiction or any circumstances in which its use would be unlawful.

Issued in Europe by Janus Capital International Limited (“JCIL”), authorised and regulated by the U.K. Financial Conduct Authority. Janus Capital International Limited (“JCIL”) is an entity registered and operating under the laws of the United Kingdom and Janus Capital Funds plc. is registered under the legislation of Ireland.

The extract prospectus (edition for Switzerland), the articles of incorporation, the extract annual and semi-annual report, in German, can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd (“FIFS”), Klausstrasse 33, CH-8008 Zurich, Switzerland, tel: +41 44 206 16 40, fax: +41 44 206 16 41, web: The Swiss paying agent is: Banque Cantonale de Genève, 17, quai de l’Ile, CH-1204 Geneva. The last share prices can be found on For Qualified investors, institutional, wholesale client use only. Outside of Switzerland, this document is for professional use only. Not for onward distribution.

This material is strictly private and confidential and may not be reproduced or used for any purpose other than evaluation of a potential investment in Janus Capital International Limited’s products or the procurement of its services by the recipient of this presentation or provided to any person or entity other than the recipient of this presentation.

We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

Janus Capital Management LLC serves as investment adviser. Janus, Intech and Perkins are registered trademarks of Janus International Holding LLC. © Janus International Holding LLC. For more information or to locate your country’s Janus representative contact information, please visit

Specific risks

  • This fund is designed to be used only as one component of several in a diversified investment portfolio. Investors should consider carefully the proportion of their portfolio invested into this fund.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund may use derivatives with the aim of reducing risk or managing the portfolio more efficiently. However this introduces other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.

Risk rating


Important message